2024
Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study
Shoukat A, Bawden C, Röst G, LeBlanc J, Galvani A, Langley J, Moghadas S. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: A Canadian Immunization Research Network (CIRN) study. Vaccine 2024, 42: 1768-1776. PMID: 38368226, DOI: 10.1016/j.vaccine.2024.02.041.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsLong-term care homesCommunity-dwelling older adultsCanadian Immunization Research NetworkIncremental cost-effectiveness ratio valuesResidents of long-term care homesRSV diseaseOlder adultsBurden of RSV diseaseRespiratory syncytial virus diseaseNo-vaccination scenarioRSV-related hospitalisationNo vaccinesRespiratory syncytial virusVaccination programBudget impactSocietal perspectiveCost-effectiveness ratioReduction of hospitalizationInfluenza vaccineRSV seasonSyncytial virusHealth benefitsAnalysis of vaccination
2023
Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
Shoukat A, Abdollahi E, Galvani A, Halperin S, Langley J, Moghadas S. Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study. The Lancet Regional Health - Americas 2023, 28: 100629. PMID: 38026446, PMCID: PMC10663690, DOI: 10.1016/j.lana.2023.100629.Peer-Reviewed Original ResearchEntire birth cohortPregnant womenBirth cohortCost-effectiveness analysisRSV seasonHigh riskBudget impactRespiratory syncytial virus diseaseSocietal perspectiveAnnual budget impactFirst RSV seasonHealth benefitsRespiratory syncytial virusImmunisation of infantsYears of ageLow budget impactMonths of ageNet monetary benefitMaternal vaccinesRSV infectionPassive immunisationGestational ageImmunisation strategiesSyncytial virusVaccine strategies